Kornimate/medical-research-clean huggingface dataset:
laser for oral mucositis in pediatric onco-hematology

Conditions: Stomatitis

Summary: children with cancer undergoing intensive chemotherapy (ct) regimens experience many side effects among which oral mucositis (om) is one of the most debilitating. modifications of ct's schedule and prolonged hospitalization may be necessary in presence of om, causing poor general conditions and debilitation. moreover, the use of narcotic analgesics and total parenteral nutrition may be required, triggering not only a physical deficit but also an economic burden. despite the frequency and impact of om among children with cancer, there is no consensus on standard therapy for this condition. previous studies demonstrated that high power laser therapy can help the maintenance of nutritional status in patients with om and can remarkably reduce costs/resources needed. laser therapy has evidence of efficacy in reducing symptoms and in preventing the onset of om in adult cancer patients but only one randomized controlled trial, with a limited number of children enrolled, supports its use in children for treatment of om induced by chemotherapy. this multicenter double-blind randomized controlled trial evaluates the efficacy of laser for treatment of oral mucositis secondary to chemotherapy in children aged 3-17 years. the study involves 8 italian hospitals.


Eligibility criteria:
inclusion criteria: * children aged 3-18 years * oral mucositis of grade 3 or 4 at enrollment (ctc - who scale) * antiblastic chemotherapy in the in the previous three weeks * willingness to undergo treatment for 4 consecutive days and to return for evaluation 7 and 11 days after enrollment. exclusion criteria: * previous treatment with laser therapy for stomatitis * presence of dysplastic oral lesions * reduction of mouth opening (\<1 cm) * localized head and/or neck radiation treatment in the previous 4 weeks * use of keratinocyte growth factor (kgf) * previous enrollment in the study

Keywords: stomatitis laser children chemotherapy treatment
continuous distal adductor canal block with periarticular local anesthetic infiltration versus continuous distal adductor canal block alone for analgesia after total knee arthroplasty

Conditions: Degenerative Osteoarthritis

Summary: continuous administration of local anesthetics to the distal adductor canal could spread into the popliteal fossa and contribute to analgesic effects on posterior knee pain. periarticular local anesthetic infiltration is a component of multimodal joint pathways and the posterior knee capsule was among the tissues routinely infiltrated. it is expected that there will be overlapping effects of distal adductor canal block and periarticular injection. therefore, we aim to compare the postoperative pain in the group that received only continuous distal adductor canal block and the group that received both continuous distal adductor canal block and periarticular injection. sixty-six patients scheduled for total knee arthroplasty will be randomly divided into the two groups. in group 1, the adductor canal catheter is inserted 2cm above the adductor hiatus. in group 2, the adductor canal catheter is inserted where the nerve block performed in group 1 and periarticular injection are performed intraoperatively.


Eligibility criteria:
inclusion criteria: 1. patients aged 19 years old or older, with american society of anesthesiologists physical status 1-3, and scheduled for elective unilateral total knee arthroplasty exclusion criteria: 1. allergy or intolerance to any of the drugs used in the study 2. hepatic or renal insufficiency 3. opioid dependency 4. coagulopathy 5. pre-existing neurologic or anatomic deficits in the lower extremities 6. severe psychiatric illness
dexamethasone palmitate for ponv after open surgery

Conditions: Postoperative Nausea and Vomiting; Dexamethasone Palmitate; Open Surgery

Summary: dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (ponv) prevention. however, ponv is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, there are still some patients still experience ponv within 24 hours postoperatively. compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. this trial aims to assess the effect and safety of preoperative dexamethasone palmitate on ponv after open surgery.


Eligibility criteria:
inclusion criteria: * aged 18 to 65 years; * providing written informed consent; * perform elective open surgery (spinal surgery, open chest surgery, open abdominal surgery) undergoing general anesthesia. exclusion criteria: * known to be allergic to dexamethasone; * any systemic glucocorticoids within 3 months before trial entry; * history of severe heart disease, liver/kidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al); * cognitive impairment or severe mental illness; * uncontrolled diabetes or infectious diseases; * pregnancy or breastfeeding.
study to assess the efficacy and safety of orismilast in psoriasis

Conditions: Psoriasis; Skin Diseases

Summary: this study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe plaque-type psoriasis. the purpose of the study is to assess the effect of orismilast modified release in moderate-to-severe plaque-type psoriasis and assess the safety aspects of these 3 different doses.the patients will receive an oral treatment of either orismilast modified release tablets or placebo tablets 2 times a day for 16 weeks.


Eligibility criteria:
inclusion criteria: 1. capable of giving signed informed consent. 2. male and female patients ≥18 years of age 3. body weight of \>40 kg 4. diagnosis of chronic, stable plaque-type psoriasis. if the patient is diagnosed with psoriasis arthritis, the arthritis should be stable. 5. moderate-to-severe plaque-type psoriasis as defined by psoriasis activity and severity index (pasi) ≥12, body surface area (bsa) ≥10%, and investigator global assessment (iga) ≥3. 6. candidate for systemic antipsoriatic treatment or phototherapy. exclusion criteria: 1. therapy-resistant psoriasis 2. unstable psoriasis or psoriatic arthritis with acute deterioration within 4 weeks of the screening visit. 3. history of allergy or hypersensitivity to any component of the study treatment. 4. active infection (eg, bacteria, viral, fungal) requiring treatment with systemic antibiotics within 4 weeks of the screening visit. 5. malignancy or history of malignancy except for treated (ie, cured) basal cell skin carcinomas.

Keywords: psoriasis orismilast
evaluation of temporomandibular joint condition post longstanding mouth opening by rubber dam

Conditions: Temporomandibular Joint Condition Post Longstanding Mouth Opening During Dental Procedure Using Rubber Dam; TMJ Disc Disorder; Osteoarthritis; Myofacial Pain

Summary: this clinical and radiographic study will be designed to evaluate the temporomandibular joint condition post longstanding mouth opening during dental procedure using rubber dam. primary outcome : preoperative and postoperative assessment of interincisal distance , occlusal biting force , visual analogue scale , lateral excursion movement and magnetic resonance imaging (mri). secondary outcome: investigator will try to answer the question of what is the best duration of time could the dentist use rubber dam isolation in dental procedures without harmful effect on tmj and its supporting structures?


Eligibility criteria:
inclusion criteria: 1. patients aged from 18 - 40 years old of both sexes. 2. no evidence of bad habits that affect occlusion like bruxism or clenching. 3. patient with normal occlusion. 4. patient free of any signs and symptoms of tmd and myofascial pain. 5. normal range of tmj movements. 6. normal biting force. exclusion criteria: 1. patient with systemic or local diseases that can affect tmj like osteoarthritis, rheumatoid arthritis, or systemic lupus erythema. 2. patient with trismus. 3. patient with recurrent dislocation of tmj. 4. swelling affects mouth opening. 5. patient came with tmj ankylosis.
insulin balanced infusion system

Conditions: Hyperglycemia; Diabetes

Summary: the purpose of this study is to study the use of a counterbalancing system of glucose and insulin infusion with frequent blood glucose monitoring and combined adaptive algorithm can produce tight glycemic control without hypoglycemia; study to develop a closed loop for use in intensive care units and surgery

the study is using an experimental design outpatient with individuals having treatment using an automated closed loop glucose control unit; glucoses are measured every 5 minutes using a intravenous glucose sensor and infusion of glucose and insulin are altered without manual intervention as directed by algorithm

Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetic individuals on insulin ages 21-85 with a1c 7-9.9% * glucose at time of study \> 150 mg/dl exclusion criteria: * pregnancy * renal or hepatic disease * corticosteroids * poor intravenous access * anemia * electrolyte abnormality

Keywords: closed loop glucose control intensive care glucose control
tipifarnib and radiation therapy in treating patients with unresectable locally advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: rationale: tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and may make them more sensitive to radiation therapy. radiation therapy uses high-energy x-rays to damage tumor cells. giving tipifarnib together with radiation therapy may kill more tumor cells. purpose: this phase i trial is studying the side effects and best dose of tipifarnib when given together with radiation therapy in treating patients with unresectable locally advanced pancreatic cancer.

objectives: primary * determine the maximum tolerated dose and dose-limiting toxic effects of tipifarnib when administered with radiotherapy in patients with unresectable locally advanced pancreatic cancer. secondary * determine the 3-month clinical response in patients treated with this regimen. outline: this is a multicenter, dose-escalation study of tipifarnib. patients receive oral tipifarnib once or twice daily on weeks 1-8. patients also undergo concurrent radiotherapy daily, 5 days a week, on weeks 2-8. cohorts of 3-6 patients receive escalating doses of tipifarnib until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. patients are followed at 1, 3, and 6 months. projected accrual: a total of 8-18 patients will be accrued for this study within 12-15 months.

Eligibility criteria:
disease characteristics: * histologically confirmed pancreatic cancer * locally advanced disease * unresectable disease requiring radiotherapy patient characteristics: age * 18 and over performance status * ecog 0-2 life expectancy * not specified hematopoietic * absolute neutrophil count ≥ 1,500/mm\^3 * platelet count ≥ 100,000/mm\^3 hepatic * ast or alt \< grade 2 elevation * bilirubin ≤ 2.0 mg/dl\* note: \*prior biliary stent procedure to normalize bilirubin levels allowed renal * creatinine ≤ 1.5 times normal other * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * hiv negative * no peripheral neuropathy ≥ grade 2 * no known allergy to imidazole drugs, including any of the following: * clotrimazole * ketoconazole * miconazole * econazole * fenticonazole * isoconazole * sulconazole * tioconazole * terconazole prior concurrent therapy: biologic therapy * not specified chemotherapy * at least 4 weeks since prior experimental or standard chemotherapy and recovered * no concurrent experimental chemotherapy endocrine therapy * not specified radiotherapy * no prior upper abdominal radiotherapy surgery * not specified

Keywords: stage ii pancreatic cancer stage iii pancreatic cancer recurrent pancreatic cancer
thought field therapy and cognitive therapy for agoraphobia

Conditions: Agoraphobia

Summary: the purpose for this study is to find out if thought field therapy has the same effect as, or better effect than, cognitive therapy for agoraphobia.

thought field therapy is an alternative treatment method that has shown, by casuistic reports, to give good results when applied for anxiety disorders. in this study 72 patients will be randomized to three groups. 24 patients will receive cognitive therapy as a control method, 24 patients will receive thought field therapy. the remaining 24 patients will wait three months, and then be randomized to either of the two therapies. before inclusion all patients will be diagnosed with m.i.n.i. and scid ii. they will fill out self evaluation forms for symptoms and quality of life, before and after treatment, and one year after treatment. all patients will undergo an interview with adis on panic and agoraphobic diagnosis and symptoms before starting treatment, and on panic and agoraphobic symptoms immediately after and one year after treatment. these interviews will be done by psychologists who are blinded for which type of treatment the patients have got.

Eligibility criteria:
inclusion criteria: * patients ages 18 years or older, * patients with agoraphobia, * patients with a score on mobility inventory "alone" of 2.5 or more, * patients who give a written consent to participate. exclusion criteria: * psychosis (past or present), * drug abuse or dependency, * moderate or high score on suicidal behaviour on the m.i.n.i., * patients who have another illness (other than panic disorder or agoraphobia) and are in need of immediate treatment.

Keywords: agoraphobia cognitive therapy thought field therapy psychotherapy research
vascular and metabolic effects of rosuvastatin

Conditions: Hypercholesterolemia

Summary: the investigators hypothesize that rosuvastatin does-dependently worsens insulin sensitivity.


Eligibility criteria:
inclusion criteria: * hypercholesterolemia exclusion criteria: * overt liver disease, chronic renal failure, hypothyroidism, myopathy, uncontrolled diabetes (hba1c \> 9%), severe hypertension, stroke, acute coronary events, coronary revascularization within the preceding 3 months, or alcohol abuse

Keywords: insulin resistance
effects of respiratory exercises in patients with hemiplegia

Conditions: Hemiplegia; Respiratory Abnormality

Summary: this study evaluates the effects of respiratory exercises on respiratory function test parameters and ultrasonographic diaphragmatic measurements. half of the hemiplegic patients will receive respiratory and neurophysiological exercises, while other half will receive only neurophysiological exercises.

after stroke, diaphragm, the most important muscle of respiration, is wasted as well as the other muscles of the affected side. ultrasonography is a non-invasive, practical, low cost utility that may measure the thickness of diaphragm in maximum expiration and inspiration thus examining the functionality of the muscle. correlation between respiratory functional tests and diaphragm ultrasonography has been proven in recent literature. in this manner, the aim of this study is twofold. first is to determine whether ultrasonography can be used practically to evaluate the respiratory functions of the patients after stroke. respiratory function tests will be used for the correlation analysis. second is to evaluate the effectiveness of respiratory exercises via diaphragm ultrasonography and respiratory function tests.

Eligibility criteria:
inclusion criteria: * stroke confirmed radiologically * unilateral hemiplegia * first stroke episode * mini mental score ≥ 24 exclusion criteria: * unable to consent and understand * chronic cardiac disease * pulmonary disease (asthma, restrictive or obstructive pulmonary disease) * facial paralysis * history of thoracic or abdominal surgery * being alcoholic * using psychotropic drugs

Keywords: hemiplegia respiratory function tests respiratory exercises diaphragm ultrasonography
short stature related distress

Conditions: Idiopathic Short Stature; Self Image

Summary: the research aims to provide data on gender-related psychological impact of gh (growth hormone)treatment. implicit measurable psychological metrics of the therapy outcome on males are to be evaluated in a prospective randomized controlled trial. as a secondary axis of the study, the investigators aim to provide descriptive documentation of the unique distress signal manifestation implicitly shown by idiopathic short stature (iss) boys and suggest methods of early detection and measurement of such manifestations that can be used to cement guidelines for the treatment in gh.

study design: a prospective randomized, double blind, placebo controlled trial design, comparing four research groups, with 4 repeated psychological measures (before treatment, after 3 months,after 1 year, and at the end of treatment, after 4 years). the study will be divided into two segments: segment 1:double blind, placebo controlled, will include the first 60 iss (idiopathic short stature)recruited patients. patients in this segment will be randomized to one of the growth hormone treatment groups in a ratio of 2:1. 40 patients will be treated 4 years with gh and 20 patients will be treated with placebo at the first year of the study and will have the option to start gh treatment after one year, for a duration of 3 years. segment 2:after the enrollment to segment 1 will end, enrollment to segment 2 will begin.participants in segment 2 (patients with iss and short stature) will serve as control groups and therefore will not be treated with growth hormone. patients in segment 2 will be evaluated only once. the 4 repeated psychological evaluations (before treatment,after 3 months, after 1 year, and at the end of treatment, after 4 years)will include the following: 1. implicit association test 2. masculine self image 3. pictures projective test 4. the rosenberg self esteem scale-a self report measure of explicit self- esteem 5. quality of life questionnaire 6. silhouette apperception technique (sat)- a self report measure assessing children's and adolescent's perception of their own body size compared with that of their age-related peers 7. child behavior checklist

Eligibility criteria:
inclusion criteria: 1 segment 1 :boys at the age range of 8-13 years 2. segment 2: boys at the age range of 12-17 years 3. tanner stage 1 (segment 1 only) 4. more than 2 sd's (standard deviation) below the average height exclusion criteria: 1. mental retardation, 2. psychiatric illness, 3. lack of informed consent\\assent. 4. health status that required chronic treatment with steroids

Keywords: idiopathic short stature self image gh therapy psychological distress
climate influence on physiotherapy in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the aim of the study was to compare the effect of inpatient physiotherapy in a warm climate versus physiotherapy in a colder climate in multiple sclerosis (ms), in both short- and long term perspectives.

empirically, several patients with ms have reported improved function in warm climate during therapy or vacation. this is in contrast to the heat intolerance frequently reported in ms. heat intolerance seems, however, to be individually distributed among the ms patients, and may seem to be related to the degree of warmth. sixty patients with gait problems and without heat intolerance were included in a cross-over study. they were randomized to a 4-week inpatient physiotherapy based on the bobath concept in norway or spain, with cross-over the year after. data from five physical performance measures and six self-reported measures were collected at screening, baseline, after treatment and three and six months after both treatment-periods. change over time within groups and comparisons of change between groups were analyzed by mixed models.

Eligibility criteria:
inclusion criteria: * between 18 and 60 years of age (both included). * multiple sclerosis according to the mcdonald criteria * disability equivalent to expanded disability status score (edss) between 4.0 and 6.5 (both included) * prepared to and considered able to follow the protocol and to attend the planned visits during the whole study period. * given written informed consent exclusion criteria: * an active ms (attack or progression) during one month prior to inclusion or start of treatment. * received treatment with glucocorticoids the last month prior to inclusion or start of treatment. * excessive fatigue or severe cognitive dysfunction related to ms that would preclude safe participation in the protocol. * suffered from major depression or any other psychiatric disorder that would preclude safe participation in the protocol. * heat intolerance. * other serious concomitant disease that could preclude safe participation in the protocol. * alcohol or drug abuse or consumption that could preclude participation according to the protocol and to attend the planned visits during the whole study period. * breastfeeding or pregnancy

Keywords: cross-over design mixed model multiple sclerosis physical performance measures physical therapy the bobath concept warm climate 6-minute walk test